Plans are also underway to begin three additional Phase Ib expansion studies focusing on different combinations and patient ...

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program ...

Medically reviewed by Jamin Brahmbhatt, MD Metastatic castration-resistant prostate cancer (mCRPC) is prostate cancer that ...

For many years, mCRPC was considered to confer a terminal prognosis, with a median survival of 12 months from development of castrate resistance. [2] However, the advent of several new agents has ...

People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment ...

Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best ...

AstraZeneca has made the decision to end the CAPItello-280 trial evaluating capivasertib in patients with metastatic castration-resistant prostate cancer.

Having detectable ctDNA before treatment is associated with worse outcomes among patients with mCRPC, regardless of the treatment they receive.

Prostate Cancer Risk Increases By 45% Among Men Who Share One Troubling Behavior The drug is intended for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC ...

The conversation wraps up with a discussion of potential future updates to this guideline, as the guideline transitions into a “living guideline” on mCRPC. Read the full guideline update, “Systemic ...

The median overall survival was 19.6 months with pembrolizumab plus docetaxel and 19.0 months with docetaxel alone. The combination of pembrolizumab and docetaxel does not improve outcomes over ...

AstraZeneca to discontinue CAPItello-280 phase III trial of Truqap in metastatic castration-resistant prostate cancer: Cambridge, UK Wednesday, April 30, 2025, 10:00 Hrs [IST] Ast ...